Abstract
Small molecular weight substances are functional, as neurotrophic factors can be developed as therapeutic drugs to treat neurodegenerative disorder. Recently, a large number of natural and synthetic neuritogenic compounds have been discovered. These compounds have various structural features, including terpenoids, lipids, alkaloids, steroid glycosides, small molecular peptides, and so on. Some of them possess not only neurotrophic properties but also neuroprotective activities. The structure-activity relationships (SARs) and mechanism of action of some important compounds have been studied intensively. Increasing experimental evidence suggests that several of these compounds can be promising candidates for drug development.
Keywords: Neuritogenic substance, Alzheimer's disease, natural products, neurotrophic factors, nerve growth factor, neuronal cells, Aging, SARs, drug development, neuroprotective, terpenoids
Mini-Reviews in Medicinal Chemistry
Title: Structural Diversity of Neuritogenic Substances and their Application Perspective
Volume: 11 Issue: 8
Author(s): J. Qi, Y. Luo and L. Gao
Affiliation:
Keywords: Neuritogenic substance, Alzheimer's disease, natural products, neurotrophic factors, nerve growth factor, neuronal cells, Aging, SARs, drug development, neuroprotective, terpenoids
Abstract: Small molecular weight substances are functional, as neurotrophic factors can be developed as therapeutic drugs to treat neurodegenerative disorder. Recently, a large number of natural and synthetic neuritogenic compounds have been discovered. These compounds have various structural features, including terpenoids, lipids, alkaloids, steroid glycosides, small molecular peptides, and so on. Some of them possess not only neurotrophic properties but also neuroprotective activities. The structure-activity relationships (SARs) and mechanism of action of some important compounds have been studied intensively. Increasing experimental evidence suggests that several of these compounds can be promising candidates for drug development.
Export Options
About this article
Cite this article as:
Qi J., Luo Y. and Gao L., Structural Diversity of Neuritogenic Substances and their Application Perspective, Mini-Reviews in Medicinal Chemistry 2011; 11 (8) . https://dx.doi.org/10.2174/138955711796268796
DOI https://dx.doi.org/10.2174/138955711796268796 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Treating Neurodegenerative Conditions Through the Understanding of Neuronal Apoptosis
Current Drug Targets - CNS & Neurological Disorders Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology Ghrelin Receptor Signaling: A Promising Therapeutic Target for Metabolic Syndrome and Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets ω -Phosphinyl-α -Amino Acids: Synthesis, and Development towards Use as Therapeutic Agents
Current Organic Chemistry The Protective Effects of Green Tea Catechins in the Management of Neurodegenerative Diseases: A Review
Current Drug Discovery Technologies Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds The Role of Inflammation in Epilepsy
Current Pediatric Reviews Tau Pathology and Future Therapeutics
Current Alzheimer Research Molecular Dynamic Study of Human Prion Protein upon D178N Mutation: New Perspective to H-bonds, Salt Bridges and the Critical Amino Acids
Protein & Peptide Letters An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias
Current Neuropharmacology Fungal Gene-Encoded Peptidase Inhibitors
Current Medicinal Chemistry Determination of Lipoic Acid in the form of 2-S-pyridinium Derivative by High-performance Liquid Chromatography with Ultraviolet Detection
Current Analytical Chemistry Evaluation of In Silico Anti-parkinson Potential of β-asarone
Central Nervous System Agents in Medicinal Chemistry Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Isolated Mitochondrial Complex I Deficiency: Explorative Data Analysis of Patient Cell Parameters
Current Pharmaceutical Design New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase
Current Protein & Peptide Science